文献速递肾癌与肾肿瘤

高危非转移性肾细胞癌术前分期模型预测病理T3期以用于新辅助临床试验入组

The Staging of High-risk and Non-metastatic Renal Cell Carcinoma Preoperatively Model Predicts Pathologic T3 Stage for Neoadjuvant Clinical Trial Enrollment.
PubMed 文献 · Urology · 2026-03-11

该研究利用2000至2024年间接受根治性肾切除术的326例非转移性肾肿瘤>7cm患者的术前腹部CT数据,开发了一个预测病理T3期的诊断模型。模型基于四个影像学特征,ROC曲线AUC为0.84,决策曲线分析显示在广泛阈值概率范围内具有临床实用性。该模型相比单纯肿瘤大小能更好识别pT3期,可能改善新辅助临床试验设计。

要点

  • 模型基于四个CT特征预测>7cm肾肿瘤的pT3期,AUC为0.84。
  • 四个特征为不规则肿瘤-脂肪界面、瘤周脂肪与对侧衰减差≥15HU、瘤周新生血管和静脉瘤栓。
  • 模型可用于优化新辅助临床试验入组,优于仅用肿瘤大小。

核心结论

  • 术前影像模型能提高>7cm肾肿瘤中pT3期的识别能力,优于单纯大小标准。

研究设计与样本

  • 回顾性分析2000至2024年连续接受根治性肾切除术的非转移性肾肿瘤>7cm患者,共326例有术前增强CT。

主要发现

  • 326例患者中位影像肿瘤直径9.1cm,59%为pT3期。
  • 四个影像特征独立预测pT3期:不规则肿瘤-脂肪界面、瘤周脂肪与对侧衰减差≥15HU、瘤周新生血管、静脉瘤栓。
  • ROC曲线AUC为0.84,决策曲线分析显示广泛阈值概率范围内有临床实用性。

关键数值与推荐

  • 模型纳入四个影像特征,AUC为0.84。
  • 瘤周脂肪与对侧衰减差阈值为≥15HU。

临床怎么用

  • 可用于>7cm肾肿瘤术前评估pT3风险,辅助新辅助临床试验入组筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a diagnostic model using preoperative abdominal CT scans that identifies pathologic T3 (pT3) stage renal cell carcinoma among patients with tumors >7 cm. Neoadjuvant clinical trials often use tumor size >7 cm for enrollment to enrich the study population with higher-risk patients. However, T stage is also an important prognostic factor, and stage pT3 tumors are associated with a significantly higher risk of metastatic progression. METHODS: Data were analyzed for consecutive patients with non-metastatic renal tumors >7 cm treated with radical nephrectomy from 2000 to 2024. Univariable and multivariable analyses were used to evaluate radiographic features for associations with pT3. A predictive model was developed, and its accuracy and clinical utility were assessed. RESULTS: A total of 326 patients with preoperative contrasted CT scans were identified. The median radiographic tumor diameter was 9.1 cm, and 59% had a pT3 stage. Four radiographic tumor characteristics were independently predictive and included in the model: 1) irregular tumor-fat interface, 2) attenuation difference of ≥15HU between the peritumor fat and contralateral side, 3) peritumor neovascularity, and 4) venous tumor thrombus. ROC curves demonstrated predictive accuracy with an AUC of 0.84. Decision curve analysis indicated clinical utility across a wide range of threshold probabilities. CONCLUSION: The Staging of High-risk And non-metastatic Renal cell carcinoma Preoperatively model improves the ability to identify stage pT3 in renal tumors >7 cm using preoperative imaging compared to size alone. This model may be used to improve neoadjuvant clinical trial design.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lotan P, Wentland AL, Shapiro DD, et al. The Staging of High-risk and Non-metastatic Renal Cell Carcinoma Preoperatively Model Predicts Pathologic T3 Stage for Neoadjuvant Clinical Trial Enrollment. Urology. 2026. PMID: 41825786. doi:10.1016/j.urology.2026.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。